Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -88.89%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.08 per share when it actually produced a loss of $0.12, delivering a surprise of -50%.Over the last four ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AQST NASDAQ Global Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commiss ...

Exhibit 99.1 Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • Met all endpoints in Phase 3 pivotal study for Anaphylm™ (epinephrine) Sublingual Film in first quarter 2024 when compared to EpiPen and other injectors used for the treatment of anaphylaxis • On track to complete Anaphylm temperature/pH study in second quarter 2024 • Received positive feedback from FDA on Anaphylm self-administration and allergen exposure protocols; remains on track to complete b ...

Met all endpoints in Phase 3 pivotal study for Anaphylm™ (epinephrine) Sublingual Film in first quarter 2024 when compared to EpiPen® and other injectors used for the treatment of anaphylaxisOn track to complete Anaphylm temperature/pH study in second quarter 2024Received positive feedback from FDA on Anaphylm self-administration and allergen exposure protocols; remains on track to complete both studies in third quarter 2024Continues to target filing an Anaphylm New Drug Application (NDA) with the FDA by th ...

Libervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients ages 2 to 5Announces immediate availability of Libervant 5mg, 7.5mg, 10mg, 12.5mg, and 15mg for patients between 2 to 5 years of ageCompany track record now includes 4 FDA approvals since 2018Anaphylm program on track; NDA submission expected by the end of 2024Hosts conference call for investors on April 29 at 8:00 a.m. ET WARREN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Aquestiv ...

WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) (the "Company" or "Aquestive"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a poster presentation highlighting the crossover study for the Company's product candidate, Libervant™ (diazepam) Buccal Film for treatment of children with epilepsy aged two to five, will be presented at the 76th Annual M ...

WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a poster presentation highlighting the crossover study for the Company’s product candidate, Libervant™ (diazepam) Buccal Film for treatment of children with epilepsy aged two to five, will be presented at the 76th Annual ...

syahrir maulana In my previous Aquestive Therapeutics (NASDAQ:AQST) article, I discussed how the company was approaching a significant milestone with the impending topline data readout for their Anaphylm (AQST-109) epinephrine sublingual film anticipated in Q1 of this year. At that time, the company had already initiated patient dosing in their Phase III pivotal study to evaluate Anaphylm’s pharmacokinetics (PK) and pharmacodynamics (PD) with the potential of a New Drug Application (NDA) filing in 2024. ...

Aquestive Therapeutics (AQST) ended the recent trading session at $4.14, demonstrating a +0.24% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily loss of 0.72%. Elsewhere, the Dow saw a downswing of 1%, while the tech-heavy Nasdaq depreciated by 0.95%.Prior to today's trading, shares of the specialty pharmaceutical company had lost 1.2% over the past month. This has lagged the Medical sector's loss of 0.03% and the S&P 500's gain of 2.16% in that time.The inv ...

Aquestive Therapeutics (AQST) closed the latest trading day at $4.38, indicating no change from the previous session's end. The stock exceeded the S&P 500, which registered a loss of 0.14% for the day. At the same time, the Dow lost 0.77%, and the tech-heavy Nasdaq gained 0.17%.The the stock of specialty pharmaceutical company has risen by 66.54% in the past month, leading the Medical sector's gain of 0.88% and the S&P 500's gain of 5.34%.Investors will be eagerly watching for the performance of Aquestive T ...